http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2242246-C2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate | 2002-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2004-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1f98cead96c900a1f9abeba063fadab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1937fe9e57e2db5db6544c55b90d5d9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d4b45341afed7503e363065ffd94a55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4c1e021448b2f207468173cc4180a9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2529ff040c09b057f7f381b7c3d3dcf1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_948a30740172c717abc655d0d78d73f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddb983de57feee8613d618dbb99c0728 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2449debca7eb63286b356c84c7b0b6f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5266f2649ead06225cd44948049685e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50f633ee032ce3d058cb1c5d6e079979 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14f13da2d3ba9ba0e3b8d169de2cd454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10d70475de38d3d98c6b0c3615153dbf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_829b5f2c469fa3f13e8ce61619a5c226 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f80e163ef07e869ce033ee2763903b3 |
| publicationDate | 2004-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2242246-C2 |
| titleOfInvention | Tableted live recombinant bivaccine "revaks vkt" against natural smallpox and hepatitis b and method for its preparing |
| abstract | FIELD: biotechnology, medicine, virology, pharmacy. n SUBSTANCE: invention proposes bivaccine comprising in a single tablet lyophilized viral material produced on the basis of the recombinant smallpox vaccine virus strain GKV № 2131 with typical properties of smallpox virus expressing preS2-Ag and HbsAg of hepatitis B virus with activity 6.5-8.0 lg CPD 50 per a tablet, lactose, sucrose, calcium stearate, vanillin, peptone, gelatose and buffer. Smallpox virus is produced in transplanted mammalian cell cultures in the following ratio of components per one tablet, wt.-%: smallpox lyophilized viral material with activity 6.5-8.0 lg CPD 50 per a tablet, 1.04-31.3; peptone, 0.12-3.8; gelatose, 0.06-1.9; sucrose, 10.1-11.55; buffer, 0.001-0.027; calcium stearate, 1.94-2.0; vanillin, 0.17-0.2; lactose, the balance, up to 100%. Method for preparing bivaccine involves passaging the strain GKV № 2131 of recombinant smallpox virus in biological system used for culturing viruses, preparing virus-containing material with titer 8.0 lg CPD 50 /ml, not less, its lyophilization with stabilizing additives, milling, mixing with filling agent and pressing. The transplanted mammalian cell culture 4647 or VERO are used as a biological system with the infection dose with the recombinant strain of smallpox virus 1.0 CPD 50 per a cell, not above. Virus is produced in monolayer of indicated mammalian cells in rollers on nutrient medium up to 50% value of cytopathic effect (CPE) followed by exchange of this medium for buffer solution with less volume as compared with volume of the nutrient medium. Preparing virus-containing material is carried out after exchange of the nutrient medium for buffer solution by extraction of viruses in three-fold freezing and thawing the cellular monolayer. As stabilizing additives in lyophilic drying peptone, sucrose and gelatose are used in their final concentration in mixture, wt.-%: 2.0-4.0; 2.0-3.0, and 1.0-3.0, respectively. Vaccine retains activity during processes of drying and tableting and comprises lesser amounts of foreign impurities. Method provides the improved technology in preparing vaccine. n EFFECT: improved preparing method. n 5 cl, 4 tbl, 7 ex |
| priorityDate | 2002-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.